Abstract: The present disclosure is generally related to separators for use in lithium metal batteries, and associated systems and products. Certain embodiments are related to separators that form or are repaired when an electrode is held at a voltage. In some embodiments, an electrochemical cell may comprise an electrolyte that comprises a precursor for the separator.

Abstract: Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the residence articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the residence article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the residence article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the residence articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the residence article includes dimensions configured for transesophageal retrieval. In some cases, the residence articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).

Abstract: The present disclosure relates to derivatized agelastatin compounds and methods for the treatment, prevention, or delay of cancer, comprising administering a therapeutically effect amount of the derivatized agelastatin compounds, a pharmaceutically acceptable salt thereof, or a composition thereof to a subject in need thereof. Methods for making the derivatized agelastatin compounds are also provided.

Abstract: A method includes receiving data representing graphomotor motion during a succession of executions of graphomotor diagnostic tasks performed in a medical context by a subject, processing the received data using a computer, including determining a first set of quantitative features from a first execution of a task by the subject, and determining a second set of quantitative features from a second execution of a task by the subject, determining one or more metrics based on a comparison to the successive executions, including using at least the first set of quantitative features and the second set of quantitative features to determine said metrics, and providing a diagnostic report associated with neurocognitive mechanisms underlying the subject's execution of the tasks based on the determined metrics.

Abstract: An alkali metal ion source with a moderate rate of release of the ion (e.g. potassium) is formed by a method that includes: 1) combining an particulate ore that contains at least one of an alkali metal ion-bearing framework silicate (e.g. syenite ore) with at least one of an oxide and hydroxide of at least one of an alkali metal and alkaline earth metal such as calcium hydroxide; 2) milling the mixture of these two components optionally, with water, optionally, milling the dry components separately and blended thereafter, optionally, with water; 3) forming a mixture by adding water to the solid mixture after milling, if water was not added before milling; 4) exposing the mixture to an elevated temperature and pressure to form a gel that includes silica and the alkali metal of the framework silicate.

Abstract: Al—Mnx/Al—Mny multilayers with a wide range of structures ranging from microcrystalline to nanocrystalline and amorphous were electrodeposited using a single bath method under galvanostatic control from room temperature ionic liquid. By varying the Mn composition by ?1-3 at. % between layers, the grain sizes in one material can be systematically modulated between two values. For example, one specimen alternates between grain sizes of about 21 and 52 nm, in an alloy of average composition of 10.3 at. % Mn. Nanoindentation testing revealed multilayers with finer grains and higher Mn content exhibited better resistance to plastic deformation. Other alloy systems also are expected to be electrodeposited under similar circumstances.

Abstract: Objects that interact with a user at a visceral level when the object comes within the user's personal environment. The objects detect a user's visceral behavior, for example breathing pattern or perspiration. In response to the visceral behavior the object simulates a behavior of a living entity such as breathing, or produces an output to which the user responds viscerally, such as an electric field. The form of the output or simulated behavior is determined by the visceral behavior. The output or simulated behavior may be modified to guide the user's visceral behavior, for example by first synchronizing simulated breathing to the user's breathing and then slowing down while the user's breathing is entrained to the simulated breathing. One such object has a skin that is warm to the touch, and simulates breathing with a breathing sound. Another such object produces electric fields like electric fields of the heart.

Abstract: The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis , etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.